Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 11/2016

01-11-2016 | Original Research Article

Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs

Authors: Cristiano Matos, Linda Härmark, Florence van Hunsel

Published in: Drug Safety | Issue 11/2016

Login to get access

Abstract

Introduction

Patient reporting of adverse drug reactions (ADRs) to spontaneous reporting systems can make a valuable contribution to pharmacovigilance. However, the implementation and promotion of patient reporting systems (PRSs) differ worldwide.

Objective

The objective of the study was to describe attitudes toward PRSs, and progress toward implementing such systems among national competent authorities participating in the World Health Organization Programme for International Drug Monitoring.

Methods

A web-based questionnaire was constructed based on qualitative interviews, and distributed through SurveyMonkey ® to all countries listed on the World Health Organization Programme for International Drug Monitoring (n = 178) during November and December of 2015. Data were analyzed using descriptive statistics and Chi-square tests.

Results

A total of 143 valid questionnaires were received from 141 countries (79.2 %). A spontaneous reporting system for both healthcare professionals and patients was present in 58 countries (41.1 %). An official PRS to report ADRs directly was implemented in 44 countries (31.2 %) and in a pilot stage in five countries (3.5 %). Patients were not allowed to report in 34 countries (24.1 %). The reasons for not having an official PRS were mainly a lack of resources/budget (56.5 %) or a lack of information/education for patients (56.5 %). When analyzing the attitudes among the respondents toward a PRS, most acknowledge that the general public contributes to the detection or strength of drug safety signals (82.2 % agree or strongly agree) and with information that is not present in healthcare professional reports (80.7 % agree or strongly agree). For respondents, giving feedback to patients could be an incentive for patients to report more (80.8 % agree or strongly agree). To be able to further PRSs, guidelines on promoting a PRS efficiently to the general public (87.4 % agree or strongly agree), training courses/conferences (86.7 % agree or strongly agree), or a public list of Lareb’s scientific publications (86.7 % agree or strongly agree) were the support measures most well accepted by the respondents.

Conclusions

Most countries accept ADR reports from patients by an official reporting system designed for patients or through the existing system for healthcare professionals. The main reasons for not having a PRS is financial restraints and a lack of information/education of patients. Attitudes toward a PRS are positive, but some countries fear that they will not be able to handle an increase in reports.
Appendix
Available only for authorised users
Literature
1.
Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38(4):337–47.CrossRefPubMed
2.
Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148–56.CrossRefPubMed
3.
van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011;20(3):286–91.CrossRefPubMed
4.
Ahmad SR. Comment on:“adverse drug reaction reporting by patients: an overview of fifty countries”. Drug Saf. 2015;38(1):109–10.CrossRefPubMed
5.
Margraff F, Bertram D. Authors’ reply to Ahmad SR:“adverse drug reaction reporting by patients: an overview of fifty countries”. Drug Saf. 2015;38(1):111.CrossRefPubMed
6.
Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–19.CrossRefPubMed
7.
8.
van Hunsel F, Härmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients. Drug Saf. 2012;35(1):45–60.CrossRefPubMed
9.
10.
Borg J-J, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? Drug Saf. 2011;34(3):187–97.CrossRefPubMed
11.
Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the pharmacovigilance system? A Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883–90.CrossRefPubMed
12.
McLernon DJ, Bond CM, Lee AJ, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf. 2011;20(5):523–31.CrossRefPubMed
13.
Robertson J, Newby DA, Robertson J. Low awareness of adverse drug reaction reporting systems: a consumer survey. Med J Aust. 2013;199(10):684–6.CrossRefPubMed
14.
15.
Fortnum H, Lee AJ, Rupnik B, Avery A. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161–5.CrossRefPubMed
16.
van Hunsel F, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. Pharmacoepidemiol Drug Saf. 2010;19(1):26–32.CrossRefPubMed
17.
Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1–10.CrossRefPubMed
18.
19.
20.
21.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrance Eribaum Association; 1988.
22.
23.
Danish Medicines Agency. The Danish Medicines Agency’s annual pharmacovigilance report 2009. Annual Report. 2010.
24.
25.
Opaleye ES, Noto AR, Zv Sanchez, et al. Recreational use of benzydamine as a hallucinogen among street youth in Brazil. Rev Bras Psiquiatr. 2009;31(3):208–13.CrossRefPubMed
26.
27.
ISOP. 11th ISoP annual meeting “Next Stop: Istanbul—Bridging the Continents”, Istanbul, Turkey, 26–28 October, 2011. Drug Saf. 2011;34(10):883–1026.
28.
Olsson MS, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and middle-income countries. Drug Saf. 2010;33(8):689–703.CrossRefPubMed
29.
30.
Krause N. A comprehensive strategy for developing closed-ended survey items for use in studies of older adults. J Gerontol Ser B Psychol Sci Soc Sci. 2002;57(5):S263–74.CrossRef
31.
Sue VM, Ritter LA. Conducting online surveys. Thousand Oaks, CA: Sage Publications; 2007.
32.
Pal SN, Olsson S, Brown EG. The Monitoring Medicines Project: a multinational pharmacovigilance and public health project. Drug Saf. 2015;38(4):319–28.CrossRefPubMedPubMedCentral
33.
Plöen M, Wallberg M, Olsson S. User-driven development of a web-based tool for patient reporting of drug-related harm. Drug Saf. 2015;38(4):359–64.CrossRefPubMed
34.
World Health Organization. Safety monitoring of medicinal products: reporting system for the general public. Geneva: WHO; 2012.
35.
Ghosh R, Lewis D. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media. Expert Opin Drug Saf. 2015;14(12):1845–53.CrossRefPubMed
36.
37.
Leone R, Moretti U, D’Incau P, et al. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study. Drug Saf. 2013;36(4):267–76.CrossRefPubMed
38.
Parretta E, Rafaniello C, Magro L, et al. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opin Drug Saf. 2014;13(Suppl. 1):21–9.CrossRef
39.
Metadata
Title
Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs
Authors
Cristiano Matos
Linda Härmark
Florence van Hunsel
Publication date
01-11-2016
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2016
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-016-0453-6

Other articles of this Issue 11/2016

Drug Safety 11/2016 Go to the issue

Original Research Article

Prevention of Medication Errors in Hospitalized Patients: The Japan Adverse Drug Events Study

Review Article

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas

Letter to the Editor

Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”

Original Research Article

A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals

Original Research Article

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients

Review Article

Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV